Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

• Published in: Circulation (New York, N.Y.) Vol. 142; no. 25; pp. 2443 - 2455
• Main Authors: Xiao, Ling, Salem, Joe-Elie, Clauss, Sebastian, Hanley, Alan, Bapat, Aneesh, Hulsmans, Maarten, Iwamoto, Yoshiko, Wojtkiewicz, Gregory, Cetinbas, Murat, Schloss, Maximilian J, Tedeschi, Justin, Lebrun-Vignes, Bénédicte, Lundby, Alicia, Sadreyev, Ruslan I, Moslehi, Javid, Nahrendorf, Matthias, Ellinor, Patrick T, Milan, David J
• Format: Journal Article
• Language: English
• Published: United States American Heart Association 22.12.2020
• Subjects: Cardiology and cardiovascular system; Human health and pathology; Life Sciences; Pharmaceutical sciences; Pharmacology; ibrutinib; BTK protein, human; atrial fibrillation; electrophysiology; protein kinase inhibitors; CSK tyrosine-protein kinase

Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly understood. We performed electrophysiology studies on mice treated with ibrutinib to assess inducibility of AF. Chemopr...